Literature DB >> 31095505

Amyloidosis causes downregulation of SorLA, SorCS1 and SorCS3 expression in mice.

Guido Hermey1, Sabine A Hoffmeister-Ullerich2, Barbara Merz1, Dagmar Groß3, Dietmar Kuhl1, Stefan Kins3.   

Abstract

Accumulation of β-amyloid peptide (Aβ) is regarded as a primary cause of Alzheimer's disease (AD). Aβ is derived by sequential cleavage of the amyloid precursor protein (APP). Alterations in the subcellular targeting of APP are thought to affect the degree of Aβ production. Sorting receptors, such as SorLA, convey subcellular targeting of APP. Dysfunction of SorLA, and likely of the related receptors SorCS1 and SorCS3, cause AD. Nevertheless, disease progression could also provoke altered expression of the receptors. Here, we assessed if Aβ plaque formation promotes altered expression of SorLA, SorCS1 and SorCS3. We analyzed transcript levels during aging and after amyloidosis in brain areas characterized by early amyloid plaque formation in an AD mouse model (APPPS1) and wild types. We observed stable expression levels during aging (1-12 months). After plaque formation, SorCS1 and SorLA expression were markedly reduced in the frontal cerebral cortex and to a minor extent in the hippocampus, whereas SorCS3 expression was solely reduced in the frontal cerebral cortex. Our results indicate that disease progression, associated with Aβ accumulation, can negatively regulate expression of the receptors.

Entities:  

Keywords:  Alzheimer’s disease; Vps10p-domain receptor; amyloid precursor protein; gene expression

Mesh:

Substances:

Year:  2019        PMID: 31095505     DOI: 10.1515/hsz-2019-0146

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  6 in total

1.  Genome-wide association study of brain arteriolosclerosis.

Authors:  Lincoln Mp Shade; Yuriko Katsumata; Timothy J Hohman; Kwangsik Nho; Andrew J Saykin; Shubhabrata Mukherjee; Kevin L Boehme; John Sk Kauwe; Lindsay A Farrer; Gerard D Schellenberg; Jonathan L Haines; Richard P Mayeux; Julie A Schneider; Peter T Nelson; David W Fardo
Journal:  J Cereb Blood Flow Metab       Date:  2022-02-14       Impact factor: 6.960

2.  Integrated analysis and network pharmacology approaches to explore key genes of Xingnaojing for treatment of Alzheimer's disease.

Authors:  Meixia Wang; Shouyong Wang; Yong Li; Gaomei Cai; Min Cao; Lanfang Li
Journal:  Brain Behav       Date:  2020-04-18       Impact factor: 2.708

3.  The adaptor protein PICK1 targets the sorting receptor SorLA.

Authors:  Lars Binkle; Marcel Klein; Uwe Borgmeyer; Dietmar Kuhl; Guido Hermey
Journal:  Mol Brain       Date:  2022-02-19       Impact factor: 4.041

4.  SorCS3 promotes the internalization of p75NTR to inhibit GBM progression.

Authors:  Yanqiu Zhang; Yue Li; Yuhua Fan; Xiaoyuan Zhang; Zhihong Tang; Jing Qi; Baoshan Zhao; Fuyuan Li; Xiaofeng Chen; Huan Liang; Haiyan Xu; Dongliang Li
Journal:  Cell Death Dis       Date:  2022-04-07       Impact factor: 8.469

5.  Converging roles of PSENEN/PEN2 and CLN3 in the autophagy-lysosome system.

Authors:  Marcel Klein; Abuzar Kaleem; Sandra Oetjen; Daniela Wünkhaus; Lars Binkle; Sandra Schilling; Milena Gjorgjieva; Ralf Scholz; Doris Gruber-Schoffnegger; Stephan Storch; Stefan Kins; Gerard Drewes; Sabine Hoffmeister-Ullerich; Dietmar Kuhl; Guido Hermey
Journal:  Autophagy       Date:  2021-12-29       Impact factor: 13.391

6.  Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women.

Authors:  Elizabeth E Blue; Timothy A Thornton; Charles Kooperberg; Simin Liu; Jean Wactawski-Wende; JoAnn Manson; Lew Kuller; Kathleen Hayden; Alexander P Reiner
Journal:  Alzheimers Dement       Date:  2020-09-23       Impact factor: 21.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.